About InVivoSIM anti-human IFNAR1 (Anifrolumab Biosimilar) This non-therapeutic biosimilar antibody uses the same variable regions from the therapeutic antibody Anifrolumab making it ideal for research use. This Anifrolumab biosimilar reacts with human IFNAR1 (IFN alpha/beta receptor subunit 1). IFNAR-1 is coexpressed with IFNAR-2 on nearly all cell types and together these two subunits make up the heterodimeric Type I IFN Receptor complex. Type I IFNs (IFN-α/β) bind to the Type I IFN Receptor complex to induce cellular responses including induction of anti-viral, anti-microbial, anti-tumor, and autoimmune responses as well as to regulate the activation, proliferation, and differentiation of many cell types. Anifrolumab is used to treat systemic lupus erythematosus (SLE) in adults. InVivoSIM anti-human IFNAR1 (Anifrolumab Biosimilar) Specifications IsotypeHuman IgG1, κ Recommended Isotype Control(s)RecombiMAb human IgG1 (K214R/L234F/L235E/P331S) isotype control, anti-hen egg lysozyme Recommended Dilution BufferInVivoPure pH 7.0 Dilution Buffer ImmunogenHuman IFNAR1 Reported ApplicationsFunctional assays Western blot ELISA FormulationPBS, pH 7.0 Contains no stabilizers or preservatives Endotoxin<0.5EU/mg (<0.0005EU/μg) Determined by LAL gel clotting assay Aggregation<5% Determined by SEC Purity>95% Determined by SDS-PAGE Sterility0.2 μm filtration ProductionPurified from cell culture supernatant in an animal-free facility PurificationProtein A Molecular Weight150 kDa StorageThe antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
